You don't have javascript enabled. Good luck with that.
Skip to content
FOR US
HEALTHCARE
PROFESSIONALS

Strongly recommended by AAD as a systemic therapy for moderate-to-severe atopic dermatitis in adult patients1

//
PEDIATRIC (AGES 12-17): EASI

Significant improvements in skin clearance and lesion extent and severity15

  • At Week 16, more than 4x as many patients treated with Adbry 150 mg q2w monotherapy achieved the primary endpoint of EASI-75 compared with placebo15
  • In ECZTRA 6, a higher proportion of subjects in the Adbry 150 mg every other week group achieved EASI-90 compared with placebo15

Pediatric patients achieving EASI-75 at Week 1615*†

Bar chart comparing the percentage of pediatric patients achieving EASI-75 at Week 16 between Adbry 150 mg and placebo. 29% of patients on Adbry 150 mg (n=98) achieved EASI-75 compared to 6% on placebo (n=94), indicating more than 4 times as many patients in the Adbry group. EASI-75 represents at least a 75% improvement in the Eczema Area and Severity Index.

EASI-75=Improvement of at least 75% in Eczema Area and Severity Index; EASI-90=Improvement of at least 90% in EASI; q2w=every 2 weeks.

*Full Analysis Set (FAS) includes all subjects randomized and dosed.
†Subjects who received rescue treatment from Week 2 to Week 16 or had missing data were considered nonresponders.

//
PEDIATRIC (AGES 12-17): IGA
  • At Week 16, more than 5x as many patients treated with Adbry 150 mg q2w monotherapy achieved the primary endpoint of IGA 0/1 compared with placebo15

Pediatric patients achieving IGA 0/1 at Week 1615*†

Bar chart comparing the percentage of pediatric patients achieving IGA 0/1 at Week 16 between Adbry 150 mg and placebo. 21% of patients on Adbry 150 mg (n=98) achieved IGA 0/1 compared to 4% on placebo (n=94), indicating more than 5 times as many patients in the Adbry group. IGA 0/1 represents a score of 0/1 on the Investigator’s Global Assessment scale.

IGA 0/1=Score of 0/1 using the Investigator’s Global Assessment scale; q2w=every 2 weeks.

*Full Analysis Set (FAS) includes all subjects randomized and dosed.
†Subjects who received rescue treatment from Week 2 to Week 16 or had missing data were considered nonresponders.

//
PEDIATRIC (AGES 12-17): NRS

Patients experienced significant itch relief at Week 1615

  • At Week 16, more than 7x as many patients treated with Adbry 150 mg q2w monotherapy experienced reduction of ≥4 points in Adolescent Worst Pruritus NRS compared with placebo15

Percentage of patients achieving a ≥4-point improvement in Adolescent Worst Pruritus NRS at Week 1615*†‡

Bar chart comparing the percentage of pediatric patients achieving a ≥4-point improvement in Adolescent Worst Pruritus NRS at Week 16 between Adbry 150 mg and placebo. 23% of patients on Adbry 150 mg (n=95) achieved this improvement compared to 3% on placebo (n=90), indicating more than 7 times as many patients in the Adbry group. NRS stands for Numeric Rating Scale.

NRS=Numeric Rating Scale; q2w=every 2 weeks.

*Full Analysis Set (FAS) includes all subjects randomized and dosed.
†Subjects who received rescue treatment from Week 2 to Week 16 or had missing data were considered nonresponders.
‡Subjects with baseline Adolescent Worst Pruritus NRS (weekly average) ≥4.

Icon of hands shaking highlighting the Adbry Advocate patient support program

Support for Your Patients

Find out how to enroll your patients in the Adbry® Advocate™ patient support program

ENROLL YOUR PATIENTS